The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials

References

• Hart M N, Earle K M. Primitive neuroectodermal tumors of the brain in children. Cancer 1973; 32(4)890–897
   Google Scholar
• Pfister S, Remke M, Toedt G, et al. Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer 2007; 46(9)839–851
   Google Scholar
• Pomeroy S L, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415(6870)436–442
   PubMed Web of Science ®Google Scholar
• McNeil D E, Cote T R, Clegg L, et al. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002; 39(3)190–194
   Google Scholar
• Bailey C C, Gnekow A, Wellek S, Jones M, Round C, Brown J, Phillips A, Neidhardt M K. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995; 25(3)166–178
   PubMedGoogle Scholar
• Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6(8)573–580
   PubMed Web of Science ®Google Scholar
• Zeltzer P M, Boyett J M, Finlay J L, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17(3)832–845
   PubMed Web of Science ®Google Scholar
• Albright A L, Wisoff J H, Zeltzer P M, et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996; 38(2)265–271
   PubMed Web of Science ®Google Scholar
• Landberg T G, Lindgren M L, Cavallin-Stahl E K, et al. Improvements in the radiotherapy of medulloblastoma, 1946–1975. Cancer 1980; 45(4)670–678
   Google Scholar
• Bouffet E, Bernard J L, Frappaz D, et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992; 24(1)79–85
   Google Scholar
• Paulino A C, Narayana A, Mohideen M N, et al. Posterior fossa boost in medulloblastoma: an analysis of dose to surrounding structures using 3-dimensional (conformal) radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46(2)281–286
   Web of Science ®Google Scholar
• Taylor R E, Bailey C C, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003; 21(8)1581–1591
   PubMed Web of Science ®Google Scholar
• Packer R J, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24(25)4202–4208
   PubMed Web of Science ®Google Scholar
• Taylor R E, Bailey C C, Robinson K J, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 2005; 41(5)727–734
   Google Scholar
• Tarbell N, Kun L, Freidman H, et al. High stage medulloblastoma: results from pediatric oncology group study 9031 (abstract). Med Pediat Oncol 2002; 39(4)227
   Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7(10)813–820
   PubMed Web of Science ®Google Scholar
• Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27(4)566–571
   PubMed Web of Science ®Google Scholar
• Jakacki R, Burger P, Zhou T, et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. Proc Amer Soc Clin Oncol 2007; 25: 2017
   Google Scholar
• Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352(10)978–986
   PubMed Web of Science ®Google Scholar
• Louis D N, Ohgaki H, Wiestler O D, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2)97–109
   PubMed Web of Science ®Google Scholar
• McManamy C S, Pears J, Weston C L, et al. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 2007; 17(2)151–164
   PubMed Web of Science ®Google Scholar
• Eberhart C G, Kepner J L, Goldthwaite P T, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94(2)552–560
   PubMed Web of Science ®Google Scholar
• Cogen P H, Daneshvar L, Metzger A K, et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 1992; 50(3)584–589
   Google Scholar
• Huang H, Mahler-Araujo B M, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000; 156(2)433–437
   Google Scholar
• Koch A, Waha A, Tonn J C, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001; 93(3)445–449
   Google Scholar
• Malkin D, Li F P, Strong L C, Fraumeni J F, Jr., Nelson C E, Kim D H, Kassel J, Gryka M A, Bischoff F Z, Tainsky M A, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250(4985)1233–1238
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulous P G, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85(6)841–851
   PubMed Web of Science ®Google Scholar
• Hamilton S R, Liu B, Parsons R E, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332(13)839–847
   PubMed Web of Science ®Google Scholar
• Raffel C, Jenkins R B, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997; 57(5)842–845
   PubMed Web of Science ®Google Scholar
• Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997; 57(11)2085–2088
   PubMed Web of Science ®Google Scholar
• Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57(13)2581–2585
   PubMed Web of Science ®Google Scholar
• Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997; 15(3)361–366
   Google Scholar
• Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150(1)1–13
   Google Scholar
• Johnson R L, Rothman A L, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272(5268)1668–1671
   PubMed Web of Science ®Google Scholar
• Evans D G, Farndon P A, Burnell L D, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64(5)959–961
   Google Scholar
• Paraf F, Jothy S, Van Meir E G. Brain tumor-polyposis syndrome: two genetic diseases?. J Clin Oncol 1997; 15(7)2744–2758
   Google Scholar
• Gilbertson R J, Ellison D W. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008; 3: 341–365
   PubMed Web of Science ®Google Scholar
• Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005; 11(1)17–22
   PubMed Web of Science ®Google Scholar
• Taipale J, Beachy P A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411(6835)349–354
   PubMed Web of Science ®Google Scholar
• Clevers H. Axin and hepatocellular carcinomas. Nat Genet 2000; 24(3)206–208
   Google Scholar
• Morin P J. beta-catenin signaling and cancer. Bioessays 1999; 21(12)1021–1030
   Google Scholar
• Zurawel R H, Chiappa S A, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998; 58(5)896–899
   Google Scholar
• Eberhart C G, Tihan T, Burger P C. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000; 59(4)333–337
   Google Scholar
• Dahmen R P, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61(19)7039–7043
   PubMed Web of Science ®Google Scholar
• Baeza N, Masuoka J, Kleihues P, et al. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003; 22(4)632–636
   PubMed Web of Science ®Google Scholar
• Ellison D W, Onilude O E, Lindsey J C, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005; 23(31)7951–7957
   Google Scholar
• Clifford S C, Lusher M E, Lindsey J C, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006; 5(22)2666–2670
   PubMed Web of Science ®Google Scholar
• Thompson M C, Fuller C, Hogg T L, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24(12)1924–1931
   PubMed Web of Science ®Google Scholar
• Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008; 3(8)e3088
   PubMed Web of Science ®Google Scholar
• Wechsler-Reya R, Scott M P. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385–428
   PubMed Web of Science ®Google Scholar
• Stone D M, Murone M, Luoh S, et al. Characterization of the human suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli. J Cell Sci 1999; 112(Pt 23)4437–4448
   PubMed Web of Science ®Google Scholar
• Koch A, Waha A, Hartmann W, et al. No evidence for mutations or altered expression of the Suppressor of Fused gene (SUFU) in primitive neuroectodermal tumours. Neuropathol Appl Neurobiol 2004; 30(5)532–539
   Google Scholar
• Reifenberger J, Wolter M, Weber R G, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58(9)1798–1803
   PubMed Web of Science ®Google Scholar
• Taylor M D, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31(3)306–310
   PubMed Web of Science ®Google Scholar
• Wetmore C, Eberhart D E, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 2000; 60(8)2239–2246
   PubMed Web of Science ®Google Scholar
• Goodrich L V, Milenkovic L, Higgins K M, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277(5329)1109–1113
   PubMed Web of Science ®Google Scholar
• Lee Y, Kawagoe R, Sasai K, et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 2007; 26(44)6442–6447
   PubMed Web of Science ®Google Scholar
• Hallahan A R, Pritchard J I, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004; 64(21)7794–7800
   PubMed Web of Science ®Google Scholar
• Schofield D, West D C, Anthony D C, et al. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol 1995; 146(2)472–480
   Google Scholar
• Nicholson J C, Ross F M, Kohler J A, et al. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 1999; 80(9)1322–1331
   Google Scholar
• Broderick D K, Di C, Parrett T J, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64(15)5048–5050
   PubMed Web of Science ®Google Scholar
• Gilbertson R J, Clifford S C. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003; 35(3)197–198
   Google Scholar
• Gilbertson R J, Langdon J A, Hollander A, et al. Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 2006; 42(5)646–649
   Google Scholar
• Grotzer M A, Janss A J, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000; 18(5)1027–1035
   Google Scholar
• Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003; 63(1)140–148
   PubMed Web of Science ®Google Scholar
• MacDonald T J, Brown K M, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29(2)143–152
   PubMed Web of Science ®Google Scholar
• Bigner S H, Mark J, Friedman H S, et al. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 1988; 30(1)91–101
   Google Scholar
• Lamont J M, McManamy C S, Pearson A D, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004; 10(16)5482–5493
   Google Scholar
• Biegel J A, Rorke L B, Packer R J, et al. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer 1989; 1(2)139–147
   Google Scholar
• Reardon D A, Michalkiewicz E, Boyett J M, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997; 57(18)4042–4047
   PubMed Web of Science ®Google Scholar
• Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001; 85(5)705–712
   Google Scholar
• Avet-Loiseau H, Venuat A M, Terrier-Lacombe M J, et al. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer 1999; 79(11–12)1843–1847
   Google Scholar
• Eberhart C G, Kratz J E, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002; 12(1)36–44
   Google Scholar
• Aldosari N, Bigner S H, Burger P C, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002; 126(5)540–544
   Google Scholar
• Boon K, Eberhart C G, Riggins G J. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005; 65(3)703–707
   Google Scholar
• Di C, Liao S, Adamson D C, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005; 65(3)919–924
   Google Scholar
• Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64(21)7787–7793
   PubMed Web of Science ®Google Scholar
• Fan X, Wang Y, Kratz J, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003; 162(6)1763–1769
   PubMed Web of Science ®Google Scholar
• Ellison D W, Clifford S C, Gajjar A, et al. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003; 7(2)53–66
   PubMedGoogle Scholar
• Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007; 13(9)2651–2657
   Google Scholar
• Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004; 22(6)984–993
   PubMed Web of Science ®Google Scholar
• Berman D M, Karhadkar S S, Hallahan A R, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297(5586)1559–1561
   PubMed Web of Science ®Google Scholar
• Romer J T, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 2004; 6(3)229–240
   Google Scholar
• Taipale J, Chen J K, Cooper M K, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406(6799)1005–1009
   PubMed Web of Science ®Google Scholar
• van Es J H, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11(11)496–502
   PubMed Web of Science ®Google Scholar
• Kimura H, Ng J M, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008; 13(3)249–260
   PubMed Web of Science ®Google Scholar